Outcomes of benign intraductal papillomas diagnosed on core biopsy: a review of 104 cases with subsequent excision from a single institution
- PMID: 30191301
- DOI: 10.1007/s00428-018-2449-3
Outcomes of benign intraductal papillomas diagnosed on core biopsy: a review of 104 cases with subsequent excision from a single institution
Abstract
A diagnosis of papilloma with atypia on core biopsy (CB) requires excision, as the risk of associated malignancy is high (average 36.9%). The management of benign intraductal papillomas (IP) diagnosed on CB is controversial due to varying upgradation rates (0-29%, average 7%) reported on excision. Our aim was to study the clinical, radiological, and pathological features associated with benign IP upgradation at our institution. An electronic data base search (keyword papilloma), from Jan. 2000-Aug. 2015 identified 258 CBs. After exclusions, 104 CBs of benign IPs with subsequent excisions from 101 females were reviewed. The clinical, radiological, and pathological features between IPs that had upgrades (defined as malignancy or atypical ductal hyperplasia) and non-upgraded IPs were compared using descriptive statistics. Studies of benign IP on CB with at least 50 follow-up excisions published between 2008 and 2016 were analyzed. Residual IP was present in 83.6% (87/104) of reviewed excisions. There were six upgrades (5.6%) (4 to malignancy (3.8%) and 2 to atypical ductal hyperplasia).Upgrades were associated with mass on imaging with a trend to significance (p = .05). Two cases with malignant upgrade had a history of contralateral cancer. An analysis of 25 published studies showed an average malignant upgrade of 5.7% (182/3164). The majority of benign IP are not upgraded on excision; thus, not all need to be excised. Those that may warrant excision are those with prior history of carcinoma, those with a mass on imaging, and/or suboptimal or imaging-discordant CB sampling.
Keywords: Atypical; Core biopsy; Papilloma; Upgrade.
Similar articles
-
Does previous history of cancer or atypia predict histologic upgrade for pure intraductal papillomas diagnosed via core biopsy? A study of 490 cases at a single institution.Cancer Rep (Hoboken). 2022 Mar;5(3):e1481. doi: 10.1002/cnr2.1481. Epub 2021 Nov 2. Cancer Rep (Hoboken). 2022. PMID: 34729946 Free PMC article.
-
Excision is indicated for intraductal papilloma of the breast diagnosed on core needle biopsy.Cancer. 2009 Jul 1;115(13):2837-43. doi: 10.1002/cncr.24321. Cancer. 2009. PMID: 19402174
-
Intraductal papillomas on core biopsy can be upgraded to malignancy on subsequent excisional biopsy regardless of the presence of atypical features.Pathol Int. 2015 Jun;65(6):293-300. doi: 10.1111/pin.12285. Epub 2015 Mar 20. Pathol Int. 2015. PMID: 25801805
-
Papillary neoplasms of the breast including upgrade rates and management of intraductal papilloma without atypia diagnosed at core needle biopsy.Mod Pathol. 2021 Jan;34(Suppl 1):78-93. doi: 10.1038/s41379-020-00706-5. Epub 2020 Oct 26. Mod Pathol. 2021. PMID: 33106592 Review.
-
Intraductal papilloma of the breast - management.Ginekol Pol. 2019;90(2):100-103. doi: 10.5603/GP.2019.0017. Ginekol Pol. 2019. PMID: 30860277 Review.
Cited by
-
Upgrade Rate and Predictive Factors for Breast Benign Intraductal Papilloma Diagnosed at Biopsy: A Meta-Analysis.Ann Surg Oncol. 2021 Dec;28(13):8643-8650. doi: 10.1245/s10434-021-10188-7. Epub 2021 Jul 30. Ann Surg Oncol. 2021. PMID: 34331160
-
Management of Breast Intraductal Papilloma Diagnosed on Core Needle Biopsy: Excision or Follow-up?Cureus. 2024 Feb 22;16(2):e54716. doi: 10.7759/cureus.54716. eCollection 2024 Feb. Cureus. 2024. PMID: 38523979 Free PMC article.
-
Analysis of the Clinical Relevance of Histological Classification of Benign Epithelial Salivary Gland Tumours.Adv Ther. 2019 Aug;36(8):1950-1974. doi: 10.1007/s12325-019-01007-3. Epub 2019 Jun 17. Adv Ther. 2019. PMID: 31209701 Free PMC article. Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical